Drug Approval | July 05, 2024
Briefs: Alembic Pharmaceuticals and Relonchem
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Dyslipidemia is a critical risk factor for cardiovascular diseases
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated
Signs MoUs with Shri Krishna Ayush University and Dabur India
This tie-up will have no impact on any other brands of the company
The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Subscribe To Our Newsletter & Stay Updated
